Immunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it’s combined with chemotherapy, a new clinical trial reports.
Those who got immunotherapy before and after surgery — along with pre-surgical chemo — had a 42% lower risk of cancer progression, recurrence or death than those who only received chemo, according to findings published Wednesday in the New England Journal of Medicine.
Further, about 25% of those who got immunotherapy and chemo had no cancer at all remaining after their surgery, compared with about 5% of those who got chemo alone.
Leave a reply